Virios plunges after fibromyalgia drug fails mid-stage study

Dogwood Therapeutics

19/09/2022 12:58

** Shares of Virios Therapeutics Inc  VIRI.O  fall 63.5% to
$3.20 premarket 
    ** Company says its antiviral drug IMC-1 was not
statistically significant in reducing pain vs placebo in
patients with fibromyalgia, a disorder characterized by
widespread pain  urn:newsml:reuters.com:*:nBw3jpN2ga
    ** The drug was designed to suppress the replication of the
herpes virus in order to lessen pain
    ** Virios says according to its analysis patients on IMC-1
showed no improvement during first half of trial during June
2021-November 2021, while it helped significantly reduce pain
between November 2021 to April 2022
    ** "We believe the interplay between different COVID-19
strains and herpes virus activation may be contributing to the
differential response we observed" - CEO Greg Duncan
    ** Company's shares up ~71% YTD

 (Reporting by Manas Mishra)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))